Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Melphalan and SCT in LCDD and IGDD
NCT00681044Phase 2Terminated
- Sponsor
- Boston Medical Center
- Start
- Oct 2006
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in light chain deposition disease (LCDD) and monoclonal immunoglobulin deposition disease (MIDD), sponsored by Boston Medical Center. Primary endpoint: Hematologic Response Rate at 1 year. Started Oct 2006; status: terminated.
02
Drugs
melphalan
03
Conditions
light chain deposition disease (LCDD)monoclonal immunoglobulin deposition disease (MIDD)
Beyond the preview
Go deeper on NCT00681044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681044.